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Abstract
 Background: There are limited data evaluating the cost-effectiveness of gastric cancer screening using 
endoscopy or upper gastrointestinal x-ray in the general population. Objective: To evaluate the cost-
effectiveness of population-based screening for gastric cancer in South Korea by decision analysis. Methods: 
A time-dependent Markov model for gastric cancer was constructed for healthy adults 30 years of age and 
older, and a deterministic sensitivity analysis was performed.  Cost-utility analysis with multiple strategies 
was conducted to compare the costs and effects of 13 different screening alternatives with respect to the 
following eligibility criteria: age at the beginning of screening, screening interval, and screening method. 
The main outcome measurement was the incremental cost-effectiveness ratio. Results: The results revealed 
that annual endoscopic screening from ages 50-80 was the most cost-effective for the male population. 
In the females, biennial endoscopy screening from ages 50-80 was calculated as the most cost-effective 
strategy among the 12 screening alternatives. The most cost-effective screening strategy may be adjustable 
according to the screening costs and the distribution of cancer stage at screening. The limitation was that 
effectiveness data were obtained from published sources. Conclusions: Using the threshold of $19,162 per 
quality-adjusted life year on the basis of the Korean gross domestic product (2008), as suggested by the 
World Health Organization, endoscopic gastric cancer screening starting at the age of 50 years was highly 
cost-effective in the Korean population. The national recommendation for gastric cancer screening should 
consider the starting age of screening, the screening interval, and the screening modality.
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Introduction
 The incidence of gastric cancer has gradually 
declined, but it remains one of the leading causes of 
cancer death worldwide (Parkin et al., 2001; Ferlay et al., 
2004). In South Korea, the age standardized incidence 
of gastric cancer is 65.7 per 100,000 people for men and 
26.0 per 100,000 people for women, which are among 
the world’s highest incidences (Shin et al., 2007). The 
5-year survival rate of early gastric cancer (EGC) exceeds 
90% (Kunisaki et al., 2006), but that of metastatic cancer 
is less than 5% (Yeh et al., 2010). Therefore, the early 
detection and treatment of gastric cancer are important 
priorities. In 1996, the first “10-Year Strategy for Cancer 
Control” was established in Korea, and organized cancer 
screening for gastric cancer was started as a National 
Cancer Screening (NCS) program in 1999 (Kim et al., 
2011). Currently, the NCS program in Korea recommends 
biennial gastric cancer screening for people older than 
40 years via direct upper-gastrointestinal x-ray (UGI 
series) or endoscopy (or both) (Kim et al., 2011). The 
median doubling time of gastric cancer is estimated as 
2–3 years (Fujita, 1978). Therefore, the optimal interval 
of screening for gastric cancer is proposed as less than 3 
years (Dan et al., 2006). The annual participation rate for 
gastric cancer screening in 2002 was 9.6% for men and 
12.9% for women, and 5 years later, the rate increased 
to 18.7% for men and 24.7% for women (Choi, 2009). 
Only 43% of people screened for gastric cancer in 2007 
underwent endoscopy, whereas 57% of people underwent 
UGI series with low sensitivity for EGC (Choi, 2009) 
consequently decreasing the effectiveness of EGC 
detection. 
 If the gastric cancer screening strategy uses 
inappropriate methods or does not consider the prevalence 
or incidence of gastric cancer in the target population, 
false positivity or false negativity will occasionally 
occur and can result in unnecessary costs or decreases 
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in the cure effect. Establishing a strategic early cancer 
screening method that considers medical and economical 
aspects is important for increasing the health of the 
population and effective allocation of resources. To create 
an effective early cancer screening strategy, a rational 
standard considering methods of examination, target 
ages, ending ages, and period of examination must be 
established, and the effectiveness of increasing the early 
cancer screening participation rate and cancer screening 
must be evaluated and administrated continuously. Korea 
is the only nation other than Japan to implement mass 
screening programs for gastric cancer. However, there 
is a paucity of data evaluating the cost-effectiveness of 
gastric cancer screening using endoscopy or UGI series 
for the general population. 
 This study aimed to explore the cost-effectiveness 
of various gastric cancer screening programs using 
endoscopy or UGI series in Korea relative to no 
screening (investigating only when there are clinical 
symptoms) and determine the most favorable screening 
alternative for gastric cancer with regard to starting age 
and screening interval. 
Materials and Methods
Markov model structure
 A time-dependent Markov model was used to 
compare hypothetical cohorts of Korean people in which 
one was followed without screening and the others 
underwent different screening strategies for gastric 
cancer. The perspective for the evaluation was societal, 
and the time horizon covered the full lifetime or up to the 
age of 99 years for the patients beginning screening at the 
age of 30 years. This cohort simulation approach with a 
cycle length of 1 year was used for running the Markov 
model. The gastric cancer incidence and mortality due 
to other causes of death (excluding gastric cancer) were 
modeled as time-dependent transition probabilities. 
 Patients moved across 10 health states. These health 
states were (1) asymptomatic healthy, (2) test-positive 
EGC, (3) test-negative EGC, (4) symptom-positive 
EGC, (5) symptom-negative EGC, (6) test-positive 
advanced gastric cancer (AGC), (7) test-negative AGC, 
(8) symptom-positive AGC, (9) symptom-negative AGC, 
and (10) dead. The probability of a patient’s transition 
from one state to another state each year was obtained 
from previously published studies. According to these 
studies, the median duration of remaining in the early 
stage is approximately 44 months, and the cumulative 
5-year risk for progressing from EGC to AGC is 63% 
(Tsukuma et al., 2000). One of the assumptions for the 
screening was that endoscopy and UGI series would 
make it possible to capture a sizable amount of cancer 
cases that would otherwise have gone undiagnosed 
until alarming symptoms developed. Thus, the model 
needed to incorporate an estimate of sojourn time when 
the cancer is screen-detectable but displays no clinical 
symptoms. We assumed a sojourn time of about 5 years 
from the previous literature (Tsukuma et al., 2000; 
Hamashima et al., 2006; ).
Alternative screening programs
 Because there are two available screening methods 
(endoscopy and UGI series) for gastric cancer in Korea, 
we considered different screening alternatives with 
regard to the following eligibility criteria: age at the 
beginning of screening and the interval between two 
screenings. All combinations of starting ages (30, 40, or 
50 years with an ending age of 80 years) and screening 
intervals (1 and 2 years) were considered, giving 12 
different screening alternatives in addition to the no-
screening option. The screening was stopped when 
the gastric cancer was detected, a participant died, or 
participants reached the age of 80 years. 
Major assumptions
 The incidence of gastric cancer is assumed to be 
similar between the screened and unscreened groups 
(Tsubono and Nishino, 2000). In the screened pathway, 
suspicious lesions detected by endoscopy were biopsied. 
If there were suspicious lesions in UGI series, then those 
people were followed by endoscopy and biopsied on 
another screening day. 
 The overall mortality and gastric cancer mortality 
were estimated using the vital statistics of Korea for 2008 
(Korea National Statistical Office, 2010). Patients who 
survived for 5 years after undergoing EGC treatment 
are assumed to have the same age- and gender-specific 
death rates as healthy people. We used the tunnel state 
to reflect the probability applied differently throughout 
the period (Hawkins et al., 2005). Stage-specific 
survival was applied differently according to the 
receipt of treatment. When the person did not undergo 
treatment due to undetected gastric cancer, his or her 
mortality was decided by the stage-specific survival 
rate in the unscreened population from the published 
data (Babazono & Hillman, 1995; Kubota et al., 2000; 
Kunisaki et al., 2006). The treatment costs of gastric 
cancer were determined according to the cancer stage. 
All patients who were diagnosed with gastric cancer were 
assumed to receive the same treatment, to pay the same 
treatment price, and to not participate in future gastric 
cancer screening.
Incidence and prevalence rates
 The gender-specific gastric cancer incidence of the 
population was obtained from Korea Central Cancer 
Registry data reported in 2008 (Korea Central Cancer 
Registry, 2010). Mortality according to age and gender 
was assessed using National Statistical Office 2008 data 
(Korea National Statistical Office, 2010). The stage 
distribution and the survival outcomes in the unscreened 
population were projected on the basis of local studies 
(Hansson et al., 1999; Kubota et al., 2000; Dan et al., 
2006; Kunisaki et al., 2006; Miyamoto et al., 2007; 
Nam et al., 2009). The corresponding outcomes for the 
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screened population were projected from clinical studies 
conducted in Korea or Japan (Kubota et al., 2000; Han 
et al., 2003; Nam et al., 2009). 
Characteristics of the screening tests
 Every person not previously diagnosed with gastric 
cancer was eligible for screening. Non-participants in 
screening and people with false-negative screening 
results were assumed to be diagnosed after the sojourn 
time had passed, and were more likely to be diagnosed 
with AGC. Based on public cancer screening data in 
Korea, the sensitivities of UGI series and endoscopy 
were 42.1 and 59%, respectively, and their specificities 
were 89.8 and 96.3%, respectively (Lee et al., 2010). 
However, a study of private screening programs reported 
the sensitivity of endoscopy was 85.4–98.8% and the 
specificity was 100% (Yeun, 1992). Therefore, we 
analyzed the sensitivity and specificity of each test by 
using the recent participation rates of private programs 
(37.1%) and public programs (62.9%) (Yeun, 1992; 
National Cancer Center, 2008; Lee et al., 2010).
Cost and effectiveness
 Costs were categorized as screening costs, initial 
treatment costs (first year), follow-up treatment costs 
(2–5 years, after 5 years), and terminal care costs (Park, 
2006). Screening costs included direct medical costs, 
nonmedical direct costs, incurred transport costs, and 
costs related to lost productivity. The treatment cost 
data for this study were obtained from a survey study 
in Korea (Table 1). The treatment costs by stage were 
assumed to be same for the unscreened and screened 
Table 1. Results of the Base Case Analysis        
Strategy of Screening for Cost ($)        Incremental       Effectiveness        Incremental C/E Incremental C/E    
Gastric Cancer (Male)             Cost ($)  (Utility)          Effectiveness                              (ICER)       
M_30_99_No screening 1,619  22.262  72.758  
M_50_80_2yr_Endoscopy 1,815 196 22.3 0.038 81.422 5,116 
M_50_80_2yr_UGI 1,836 20 22.297 -0.003 82.35 (Dominated) 
M_50_80_1yr_Endoscopy 1,975 159 22.333 0.033 88.457 4,820 
M_40_80_2yr_Endoscopy 1,977 2 22.308 -0.025 88.663 (Dominated) 
M_50_80_1yr_UGI 2,009 34 22.324 -0.009 90.037 (Dominated) 
M_40_80_2yr_UGI 2,017 42 22.305 -0.029 90.466 (Dominated) 
M_30_80_2yr_Endoscopy 2,206 230 22.313 -0.02 98.878 (Dominated) 
M_30_80_2yr_UGI 2,278 303 22.307 -0.026 102.143 (Dominated) 
M_40_80_1yr_Endoscopy 2,295 320 22.349 0.016 102.721 20,490 
M_40_80_1yr_UGI 2,369 74 22.337 -0.011 106.087 (Dominated) 
M_30_80_1yr_Endoscopy 2,760 464 22.355 0.006 123.485 81,294 
M_30_80_1yr_UGI 2,890 129 22.342 -0.012 129.364 (Dominated) 
Without dominated options (simple or extended)      
M_30_99_No screening 1,619  22.262  72.758  
M_50_80_1yr_Endoscopy 1,975 355 22.333 0.071 88.457 4,979 
M_40_80_1yr_Endoscopy 2,295 320 22.349 0.016 102.721 20,490 
M_30_80_1yr_Endoscopy 2,760 464 22.355 0.006 123.485 81,294 
Strategy of Screening for  Cost ($)         Incremental       Effectiveness          Incremental C/E           Incremental C/E   
Gastric Cancer (Female)              Cost ($)  (Utility)            Effectiveness      (ICER)     
F_30_99_No screening 774  23.81  32.515  
F_50_80_2yr_Endoscopy 977 202 23.828 0.018 41.005 11,378 
F_50_80_2yr_UGI 999 22 23.827 -0.002 41.936 (Dominated) 
F_40_80_2yr_Endoscopy 1,109 132 23.834 0.006 46.543 21,014 
F_40_80_2yr_UGI 1,146 37 23.832 -0.002 48.121 (Dominated) 
F_50_80_1yr_Endoscopy 1,164 55 23.844 0.009 48.839 6,073 
F_50_80_1yr_UGI 1,206 42 23.839 -0.004 50.624 (Dominated) 
F_30_80_2yr_Endoscopy 1,290 125 23.84 -0.004 54.13 (Dominated) 
F_30_80_2yr_UGI 1,352 187 23.836 -0.007 56.722 (Dominated) 
F_40_80_1yr_Endoscopy 1,425 261 23.855 0.012 59.766 22,283 
F_40_80_1yr_UGI 1,499 73 23.849 -0.006 62.871 (Dominated) 
F_30_80_1yr_Endoscopy 1,791 365 23.863 0.007 75.055 50,033 
F_30_80_1yr_UGI 1,908 117 23.856 -0.007 80.004 (Dominated) 
Without dominated options (simple or extended)      
F_30_99_No screening 774  23.81  32.515  
F_50_80_2yr_Endoscopy 977 202 23.828 0.018 41.005 11,378 
F_50_80_1yr_Endoscopy 1,164 187 23.844 0.015 48.839 12,188 
F_40_80_1yr_Endoscopy 1,425 261 23.855 0.012 59.766 22,283 
F_30_80_1yr_Endoscopy 1,791 365 23.863 0.007 75.055 50,033 
C/E, cost effectiveness ratio; ICER, incremental cost effectiveness ratio; UGI, upper-gastrointestinal x-ray.    
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populations. All estimated costs are expressed using an 
exchange rate of 1103 Korean won to 1 United States 
dollar, which was the annual exchange rate in 2008. To 
capture both the mortality and morbidity outcomes due 
to gastric cancer screening, health improvement was 
measured in quality-adjusted life years (QALYs). The 
quality of life according to gastric cancer stage was 
obtained from several published articles (Dan et al., 
2006; Hanmer et al., 2006). The survival rate according 
to stage was calculated using the 5- or 10-year survival 
rates from a synthesis of published studies (Babazono & 
Hillman, 1995; Kim et al., 2000; Kunisaki et al., 2006; 
Miyamoto et al., 2007).
 
Statistics and sensitivity analysis
 Comparisons were made between the reference 
strategy of no screening for the population and different 
screening strategies using endoscopy or UGI series. A 
discount rate of 3% for costs and effects was applied to 
the analyses. Final outcome measures were incremental 
cost-effectiveness ratios (ICERs) expressed as $/QALY. 
All of the base case estimates including the sensitivity 
and specificity of each screening program were varied 
over a wide range during the sensitivity analyses. The 
ranges for sensitivity analysis were based on the range 
of variables in all relevant studies. When published data 
were not available, base case estimates were halved and 
doubled, with additional adjustment made by author 
consensus. One-way sensitivity analysis was applied to 
the base case population of Korea to identify the factors 
that had the greatest impact on cost-effectiveness and to 
determine the impact of assumptions and estimations for 
all variables used. Analysis was performed using Data 
2009 (Treeage Software Inc, Williamstown, MA).
Results 
Base case results
 The 1-year-interval UGI series screening strategy 
from ages 30 to 80, calculated through the Markov model, 
resulted in the highest cost of $2890 for males and $1908 
for females, and utility was highest for annual endoscopy 
from ages 30 to 80 with 22.355 QALY for males and 
23.863 QALY for females (Table 1). 
 Compared to the no screening alternative, the ICER 
of the endoscopic screening alternative with a 2-year 
interval from ages 40 to 80 for the male population was 
$7673/QALY. Additionally, compared to the no screening 
alternative, the ICER of UGI series from ages 40 to 80 
with a 2-year interval was estimated to be $9292/QALY 
for the male population. The cost-effectiveness results 
are displayed graphically in Figure 1. 
 Based on commonly accepted thresholds of society’s 
willingness to pay per QALY of $19,162, the endoscopic 
gastric cancer screening at the starting age of 50 years 
may be highly cost-effective in the Korean population. 
Comparing the net health benefit among these strategies, 
annual endoscopic screening for Korean men from ages 
50 to 80 was the most cost-effective strategy for the 
defined willingness-to-pay threshold (Figure 2). The 
ICER of this strategy over no screening was $4979/
QALY.
Effectiveness (QALY), Male Effectiveness (QALY), Female 
Figure 1. Comparing Different Alternatives of Gastric Cancer Screening
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Figure 2. Gastric Cancer Screening Strategy Graph on Willingness-to-Pay
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Table 3. Sensitivity Analysis (Korean Population Screening)              
                                                 Sensitivity analysis range  50 to 80 years, Endoscopy ICER (Male) 50 to 80 years, Endoscopy ICER (Female)     
             2-yr interval       1yr interval            2-yr interval         1-yr interval 
 Min Max  Min Max  Min Max  Min Max  Min Max
Endoscopy + Consultation cost ($) 19.68 78.72  (Ext Dom) 6,558  3,307 18,695    7,618 14,733  7,828 17,968
UGI + Constulation cost ($) 18.57 74.28  (Ext Dom) (Ext Dom)  8,303       4,979   (Ext Dom) 11,378  18,918 1      2,188
Biopsy cost ($) 12.27 49.08  (Ext Dom) (Ext Dom)  4,955 5,028  11,328 11,480  12,122 12,321
EGC first year treatment cost ($) 2,996 11,982  (Ext Dom) (Ext Dom)  4,595 5,748  11,050 12,036  11,865 12,836
EGC first year productivity loss cost ($) 0 9,301  (Ext Dom) (Ext Dom)  3,786 4,979  10,358 11,378  11,183 12,188
EGC 2-5 year treatment cost ($) 369 1,476  (Ext Dom) (Ext Dom)  4,853 5,232  11,268 11,599  12,079 12,407
EGC 2-5 year productivity loss cost ($) 0 3,825  (Ext Dom) (Ext Dom)  3,671 4,979  10,236 11,378  11,058 12,188
AGC first year treatment cost ($) 5,817 23,270  (Ext Dom) (Ext Dom)  5,382 4,174  11,688 10,759  12,582 11,400
AGC first year productivity loss cost ($) 0 18,773  6,268 (Ext Dom)  6,292 4,979  12,378 11,378  13,460 12,188
AGC 2-5 year treatment cost ($) 1,690 6,760  (Ext Dom) (Ext Dom)  5,202 4,535  11,550 11,035  12,416 11,733
AGC 2-5 year productivity loss cost ($) 0 10,398  6,303 (Ext Dom)  6,400 4,979  12,435 11,378  13,590 12,188
After 5 year treament cost ($) 636 2,543  (Ext Dom) (Ext Dom)  5,037 4,864  11,416 11,303  12,261 12,042
After 5 year productivity loss cost ($) 0 5,136  (Ext Dom) (Ext Dom)  5,446 4,979  11,683 11,378  12,778 12,188
Treatment cost for last one year ($) 3,980 15,921  (Ext Dom) (Ext Dom)  5,261 4,417  11,639 10,857  12,423 11,718
Productivity loss cost for last 1 year (male) 0 8,049  (Ext Dom) (Ext Dom)  5,548 4,979       - -  - -
Productivity loss cost for last 1 year female) 0 4,829  - -  -     -  11,695 11,378  12,474 12,188
Endoscopy sensitivity (%) 59.00% 98.80%  (Ext Dom) (Ext Dom)  5,241 4,492    11,945  (Ext Dom)  13,812 10,267
Endoscopy specificity (%) 96.30% 100.00%  (Ext Dom) (Ext Dom)  5,008 4,932  11,444 11,271  12,264 12,064
UGI sensitivity (%) 42.10% 90.80%  (Ext Dom) (Ext Dom)  4,979 4,979  11,378 11,378  12,188 12,188
UGI specificity (%) 81.20% 90.10%  (Ext Dom) (Ext Dom)  4,979 4,979  11,378 11,378  12,188 12,188
Endoscopy compliance (%) 45.00% 85.00%  5,234 (Ext Dom)  5,273 4,707  11,405 11,354  12,507 11,914
UCI compliance (%) 45.00% 85.00%  (Ext Dom) (Ext Dom)  4,979 4,979  11,378 11,378  12,188 12,188
5 yr progression risk from EGC to AGC 48.10% 77.90%  (Ext Dom) (Ext Dom)  4,958 5,067  11,575 11,277  12,271 12,123
No screen : EGC proportion 7% 39%  (Ext Dom) (Ext Dom)  2,067 5,237  7,475 11,714  7,592 12,606
No screen : AGC proportion 61% 93%  (Ext Dom) (Ext Dom)  5,237 2,067  11,714 7,475  12,606 7,592
Screen : EGC proportion 52% 86%  15,349 (Ext Dom)  16,021 4,622  25,762 10,884  29,096 11,640
Screen : AGC proportion 14% 48%  (Ext Dom) 15,349  4,622 16,021  10,884 25,762  11,640 29,096
No screen : survival data (EGC) 78.2%(5yrs) 92.6%(5yrs)  (Ext Dom) (Ext Dom)  4,729 4,981  11,035 11,381  11,418 12,194
No screen : survival data (AGC) 24.5%(5yrs) 35.1%(10yrs) (Ext Dom) (Ext Dom)  6,290 4,577  11,912 11,243  12,647 12,082
Screen : survival data (EGC) 93.9%(5yrs) 98.4%(5yrs)  (Ext Dom) (Ext Dom)  5,099 4,845  11,595 11,134  12,481 11,862
Screen : survival data (AGC) 60.1%(5yrs) 61.8%(10yrs) (Ext Dom) (Ext Dom)  4,817 5,393  11,322 11,507  12,155 12,260
EGC symptom develop probability 10% 40%  (Ext Dom) (Ext Dom)  4,676 5,149  10,655 11,784  11,302 12,684
AGC symptom develop probability 56% 90%  (Ext Dom) (Ext Dom)  5,424 2,776  11,705 9,759  12,528 10,526
Normal utility (QALY) 0.782 0.918  (Ext Dom) (Ext Dom)  4,979 4,979  11,378 11,378  12,188 12,188
EGC utility (QALY) 0.65 0.85  (Ext Dom) (Ext Dom)  6,551 4,698  14,817 10,755  16,009 11,502
AGC utility (QALY) 0.17 0.7  (Ext Dom) (Ext Dom)  4,368 5,483  10,213 12,300  10,729 13,383
Discount rate (%) 1% 5%  (Ext Dom) (Ext Dom)  3,544 6,791  8,393 15,141  8,922 16,322
Note: Sensitivity analysis was performed to cover the widest reasonable range of variables in the literature; ICER, incremental cost effectiveness 
ratio; Min, minimum value; Max, maximum value; Ext Dom, extended dominated; UGI, upper-gastrointestinal x-ray; EGC, early gastric cancer; 
AGC, advanced gastric cancer; QALY, quality-adjusted life year.            
 The cost for a woman in the unscreened population 
was $774, and the effect was 23.810 QALY. Compared to 
the no screening alternative, the ICER of the endoscopic 
screening alternative with a 2-year interval from the 
age of 40 to 80 for females, which is one of the national 
guidelines for gastric cancer screening, was $13,892/
QALY. Compared to the no screening alternative, the 
ICER of UGI series from the age of 40 to 80 with a 
2-year interval for the female population was estimated 
to be $16,844/QALY. The 2-year-interval endoscopic 
screening of Korean women from the age of 50 to 80 was 
the most cost-effective screening strategy for the defined 
willingness-to-pay threshold (Figure 2). The ICER of this 
strategy over no screening was $11,378/QALY.
Sensitivity analysis
One-way sensitivity analyses were performed with a 
maximum value and minimum value for each parameter, 
with discounting rates of 1 and 5% and varying 
the screening and treatment costs by 50 or 200%. 
Cost-effectiveness was most sensitive to the cost of 
endoscopic screening or UGI series and the distribution 
of cancer stage at screening (Table 2). When the cost 
of endoscopic screening was doubled, the most cost-
effective alternative for males was UGI series screening 
with a 2-year interval from the age of 50 to 80, and 
compared to the no screening alternative, the ICER of 
that strategy was $6558/QALY. In the same condition for 
females, the UGI series screening with a 2-year interval 
from the age of 50 to 80 was the most cost-effective 
alternative, and the ICER of this strategy was $14,733/
QALY compared to the no screening alternative. The 
cost-effectiveness ratio of gastric cancer screening from 
ages 50 to 80 using endoscopy appeared to be acceptable 
as a public policy.
Discussion
The NCS program was started in Korea under an 
initiative of the Ministry of Health and Welfare (Ministry 
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of Health and Welfare Republic of Korea, 2004). 
However, there is a paucity of information regarding 
the cost-effectiveness of a mass screening program for 
gastric cancer using endoscopy or UGI series. Therefore, 
this research evaluated the cost and utility of mass gastric 
cancer screening programs to help plan gastric cancer 
screening strategies. 
World Health Organization choosing interventions 
that are cost effective (WHO-CHOICE) suggested 
the very cost-effective threshold would be less than 
gross domestic product income per capita in relevant 
population(World Health Organization, 2001). Using 
this threshold of $19,162 per person in Korea (2008) 
(International Monetary Fund (IMF), 2011), the mass 
screening strategy of endoscopy for both men and women 
over 50 is very cost-effective in Korea. In our base case 
model, we demonstrated that gastric cancer screening 
from the age of 50 to 80 in males via annual endoscopy 
is the most cost-effective with an ICER of $4979/QALY. 
The ICER of the screening strategy for women from the 
age of 50 to 80 using biennial endoscopy was $11,378/
QALY. Based on our results, the optimal age (40 years 
old) to initiate screening should be reconsidered, as the 
cost-effectiveness was improved for older people because 
the incidence of gastric cancer increases rapidly with 
increasing age. 
A previous study in Japan demonstrated that an 
indirect X-ray method ($29) was more cost-effective than 
direct radiography ($96) and endoscopy ($80) in 1995 
(Babazono & Hillman, 1995). This study also reported 
that screening 40-year-old men and women was less 
cost-effective than beginning screening at the age of 
50, consisting with our findings. The cost of endoscopy 
may be different in different countries: $80 in Japan 
(1995), approximately $150 (2006) in Singapore, and 
approximately $300 (2006) in the USA. These costs were 
almost 3- to 9-fold higher than that in Korea. Endoscopic 
screening exhibited more sensitivity and specificity than 
UGI series in Korea, with a positive predictive value of 
98-99.8% (Kim et al., 2000). Although UGI series may 
have clinical utility as an alternative method of gastric 
cancer screening and endoscopy has a weakness in terms 
of discomfort during the procedure, UGI series strategies 
were dominated by endoscopic screening strategies in 
our results. Thus, in our model, endoscopy is more cost-
effective than UGI series despite their approximately 
equal costs. Endoscopy appears to be optimal as the 
first-line method for gastric cancer screening in Korea. 
Our results recommend that the current national guideline 
for the use of UGI series to screen people 40 years old 
or older should be re-evaluated in Korea. 
The costs, availability, and accessibility of endoscopy 
are very different in different countries. Although 
endoscopy is widely available in major cities in China, 
its availability and accessibility are limited in rural areas 
(Leung et al., 2008). By contrast, mass screening using 
endoscopy was reported to be unfeasible in Japan because 
of a lack of experienced endoscopists and the insufficient 
governmental support system (Leung et al., 2008). A 
study in Singapore suggested endoscopic screening only 
for moderate-to-high-risk groups (Yeh et al., 2010). The 
cost of endoscopy is the major modifiable factor that 
affects the cost-effectiveness of a screening program. As 
this study is a country-specific economic evaluation, the 
interpretation and generalization of our results to other 
countries should be cautiously approached. Whether 
such mass screening programs for gastric cancer using 
endoscopy or UGI series are cost-effective and actually 
reduce the mortality of gastric cancer in other countries 
remains to be researched. 
We made conservative estimates to decrease the bias 
relative to the screened group. For example, previous 
research reported that repetitive cancer screening 
increases the likelihood of detecting EGC; however, we 
applied the same gastric cancer stage distribution in the 
screening arms. In reality, some cases of EGC can be 
treated via endoscopic mucosal resection, which would 
result in lower costs and a higher quality of life (Probst 
et al., 2009). The costs of treatment according to cancer 
stage were assumed to be similar without considering 
whether screening was performed.
Several limitations for this research should be 
mentioned. First, the results of this study were 
produced by a computer simulation program, which 
uses many assumptions. For instance, effectiveness 
data were obtained from reports from others (Dan et 
al., 2006; Hanmer et al., 2006). However, to qualify the 
uncertainty of the utility of the health status, we analyzed 
sensitivity over a wide range of effectiveness. Second, 
the infrastructure for mass gastric cancer screening is 
already in place in Korea, so the cost of installing a 
screening program was not considered in this research. 
However, if a new gastric cancer screening program is 
implemented by a government, the cost of establishing 
the basic infrastructure should be considered. In addition, 
the cost of lost productivity per case of gastric cancer 
should be considered from the societal or national 
perspectives of the patient group. In this study, the 
outcomes were not considered heterogeneous in regards 
to economic status, which requires additional study. 
Finally, the additional changes in the cost-effectiveness 
due to examining the incidence of reflux esophagitis, 
gastritis, and Helicobacter pylori infection (Gersonet 
al., 2004) which can be detected coincidently by these 
gastric cancer screening strategies, were not considered. 
However, we do not believe that including these factors 
would significantly change the risks according to the 
use of screening. 
Screening for gastric cancer using endoscopy from 
ages 50 to 80 may be very cost-effective in the Korean 
population. The cost-effectiveness of gastric cancer 
screening was most sensitive to the cost of endoscopic 
screening and the distribution of cancer stage diagnosis. 
It is important that policymakers monitor the cost-
effectiveness of several alternatives according to 
gender, starting age of screening, screening interval, 
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